R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)
@rbryanbell
Followers
3K
Following
8K
Media
676
Statuses
4K
Cancer Institute Director. Head & Neck Surgeon. Clinical Researcher focused on #immunotherapy. Relentlessly working to #FinishCancer @Providence Tweets my own
Portland, OR
Joined December 2015
I am deeply honored to succeed Dr. Urba & I am committed to building upon his legacy of transformational immuno-oncology research & a world-class cancer center dedicated to translating the next generation of immunotherapies from lab bench to the bedside. @ChilesResearch.
Providence is excited to announce Bryan Bell, M.D., as executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute @ChilesResearch. Walter Urba, M.D., Ph.D., wll retire at the end of the year.
13
5
50
Kolby and Kinslee raised over $100 for cancer research on behalf of their granddad, Mark Williams, who is 17 year survivor of metastatic melanoma, treated with immunotherapy @providence. I think that must be the best lemonade ever made. Thank you! ❤️🙏🍋
0
0
9
New Study published in @NaturePortfolio: @Providence whole genome sequencing program shows transformative potential for population health and provides a roadmap for the early detection and prevention of cancer @ChilesResearch
0
0
2
Congratulations to Dr. Michael Gough & Team @Nature. This work leverages the use of mathematical modeling to explore the complexity of immune responses between individuals & of an explant system as a tool to rapidly evaluate patient responses.
0
0
2
@jitcancer vision: Opportunities for deeper understanding of anti-tumor activity, toxicity & resistance to optimize cancer immunotherapy. Great work from @sitcancer visionaries including our own Dr. Will Redmond. @ChilesResearch
0
1
3
RT @DrUppaluri: Here it is! KEYNOTE-689 primary publication online now @NEJM. It’s been an incredible journey with DAdkins @SitemanCenter @….
0
30
0
Long-Term Follow-Up of E3311, an @eaonc Phase II Trial of Transoral Surgery + risk adapted adjuvant therapy. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS.
0
4
13
Boom!💥 @FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma, ushering in a new standard of care for the first time in decades.
0
21
35
This work on DARK MATTER represents a real shift in thinking about which antigens are important in anti-tumor immune responses and is a rapidly evolving field within tumor immunology. Proud of our experts from @ChilesResearch, Bernie Fox & Rom Leidner for helping to lead it.
#SITC25 Science Preview: Join @BernardAFox @ChilesResearch, Christopher A. Klebanoff, MD @MSKCancerCenter, Rom S. Leidner, MD @ChilesResearch, Catherine Wu, MD @DanaFarber to describe novel cancer antigens derived from the dark genome. Browse details:
0
0
3
Delighted to present path response from our Neoadjuvant ImmunoRadioTherapy (NIRT-2) trial in pts w HPV- HNSCC @ASCO.mPR=71%.pCR=29%.Downstaging=67%.Omission of adjuvant RT=83%.Surgical de-escalation=50%.@ChilesResearch @UCSDCancer_COE @CalifanoMd.#ASCO25.
4
14
41
If surgeons interpret NIVOPOSTOP as a good excuse to “just give immunotherapy after surgery”, they will be denying many pts the potential benefit of downstaging from NEOADJUVANT immunotherapy, elimination of chemo in some & a reduction in the rate of distant metastasis. #ASCO2025.
0
0
1
Great to be @ASCO for yet another plenary session featuring HNSCC. NIVOPOSTOP is POSITIVE! Exciting advance & option for high risk resected HPV- pts. But given the EFS benefit & reduction in DM seen in KN689 for stage 3 pts in particular, these results/trials are not equivalent.
1
1
4
Adjuvant Cemiplimab better than Placebo in High-Risk Cutaneous SCC, giving more options for patients. Given that KN630 was negative in a similar, but not identical study group (c-post has higher risk pts), an important lesson in trial design. @NEJM
1
2
12
If you are attending @AHNSinfo, please join Dr. Stephen Lai & me this evening (Wed) in Celestin E at 6:15pm for updates on @NRGonc HN006 AND to hear PRACTICE CHANGING data from Keynote 689, the Ph3 trial of perioperative pembrolizumab recently presented @AACR by @DrUppaluri
0
2
11
Great to be @AHNSinfo Annual meeting. Watch for the Immunotherapy session on Wed in which @ChilesResearch IO Fellow Robert Herman will present updated survival from our Ph1 NIRT study. In addition, I will present data from KN689 during the evening sessions at 6pm!
0
2
6
RT @HemOncToday: “It’s really exciting. It’s a new frontier for our patients.” . @DrUppaluri of @DanaFarber discussed data from KEYNOTE-689….
0
4
0
Adoptive cellular therapy is one of the pillars of our clinical & research programs @providence cancer institute, including this in house product being developed @ChilesResearch. Proud of the work our teams are doing to #FinishCancer with the power of the immune system. @agon_ox.
Dr Andy Weinberg @ChilesResearch & @agon_ox opens the #TVACT2025 at @UHCancerCenter #Honolulu - 30 yrs since 1st #TVACT1995/Shows expansion of Tu-Rx CD39+/CD103+ TIL/finds 150 unique TCR in #Melanoma pt/Diverse TCR repertoire/What are they recognizing? #cancer #immunotherapy
0
0
3
Great discussion by @RobertFerrisMD who poses compelling questions to move the field forward, deepen path response & enhance survival in LA HNSCC. With a new IO based neoadjuvant IO foundation upon which to build, is the future IO-IO? Chemo-IO? Or…lymphatic sparing SBRT-IO? 😏
1
0
8
A great day for patients & the field! @DrUppaluri presents data from KN689 showing improved survival (HR=0.66) & major pathologic responses (~10%) in resectable locally advanced HNSCC treated w perioperative pembrolizumab. These data will result in a new standard of care. @AACR
2
14
37